Page last updated: 2024-08-24

valsartan and Hyperglycemia, Postprandial

valsartan has been researched along with Hyperglycemia, Postprandial in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (37.50)29.6817
2010's4 (50.00)24.3611
2020's1 (12.50)2.80

Authors

AuthorsStudies
Abdo, VB; Ashour, RH; Elshenawy, DSA; Ramadan, NM1
Chang, KH; Dikalova, AE; Engberding, N; Griendling, KK; Jo, H; Koga, M; Lassègue, B; Long, JS; Seidel-Rogol, B1
Aoyama, I; Bomsztyk, K; Komers, R; Koopmeiners, JS; Naito, M; Schnaper, HW; Shenoy, A1
Fliser, D; Frank, H; Heemann, U; Pscherer, S1
Huang, J; Matavelli, LC; Siragy, HM1
Ofili, EO; Purkayastha, D; Samuel, R; Sowers, JR; Zappe, DH1
Chan, P; Cheng, JT; Liu, IM; Tzeng, TF; Wong, KL; Yang, TL1
Dallinga-Thie, GM; de Koning, EJ; Gaillard, CA; Rabelink, TJ; van Zonneveld, AJ; Westerink, JW; Willemsen, JM1

Trials

1 trial(s) available for valsartan and Hyperglycemia, Postprandial

ArticleYear
Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic combination therapy in obese, hypertensive African American and white patients.
    American journal of therapeutics, 2013, Volume: 20, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Black or African American; Blood Glucose; Diuretics; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hyperglycemia; Hypertension; Insulin; Intention to Treat Analysis; Male; Middle Aged; Obesity, Abdominal; Prediabetic State; Tetrazoles; Treatment Outcome; Valine; Valsartan; White People

2013

Other Studies

7 other study(ies) available for valsartan and Hyperglycemia, Postprandial

ArticleYear
Sacubitril/valsartan combination enhanced cardiac glycophagy and prevented the progression of murine diabetic cardiomyopathy.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 153

    Topics: Aminobutyrates; Animals; Biphenyl Compounds; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Drug Combinations; Glycogen; Heart Failure; Hyperglycemia; Mice; Rats; Stroke Volume; Tetrazoles; Valsartan

2022
The bone morphogenic protein inhibitor, noggin, reduces glycemia and vascular inflammation in db/db mice.
    American journal of physiology. Heart and circulatory physiology, 2013, Sep-01, Volume: 305, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blood Pressure; Bone Morphogenetic Proteins; Carrier Proteins; Diabetes Mellitus, Type 2; Disease Models, Animal; Hyperglycemia; Male; Mice; Mice, Mutant Strains; Reactive Oxygen Species; Tetrazoles; Valine; Valsartan; Vasculitis

2013
High ambient glucose augments angiotensin II-induced proinflammatory gene mRNA expression in human mesangial cells: effects of valsartan and simvastatin.
    American journal of nephrology, 2009, Volume: 30, Issue:2

    Topics: Angiotensin II; Gene Expression Regulation; Glucose; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Inflammation; Kidney; Mesangial Cells; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin; Tetrazoles; Valine; Valsartan

2009
Effect of experimental hyperglycaemia on renal haemodynamics in prediabetic patients with and without AT1 receptor blockade.
    European journal of clinical investigation, 2010, Volume: 40, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Case-Control Studies; Glomerular Filtration Rate; Glucose Tolerance Test; Humans; Hyperglycemia; Male; Middle Aged; Prospective Studies; Receptor, Angiotensin, Type 1; Renal Circulation; Tetrazoles; Treatment Outcome; Valine; Valsartan; Young Adult

2010
Renal (pro)renin receptor contributes to development of diabetic kidney disease through transforming growth factor-β1-connective tissue growth factor signalling cascade.
    Clinical and experimental pharmacology & physiology, 2011, Volume: 38, Issue:4

    Topics: Animals; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glucose; Hyperglycemia; Male; Mesangial Cells; Oligopeptides; Prorenin Receptor; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptors, Cell Surface; RNA, Small Interfering; Signal Transduction; Tetrazoles; Transforming Growth Factor beta1; Up-Regulation; Valine; Valsartan

2011
Antihyperglycemic action of angiotensin II receptor antagonist, valsartan, in streptozotocin-induced diabetic rats.
    Journal of hypertension, 2003, Volume: 21, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Glucose; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Disease Models, Animal; Gene Expression; Glucose Tolerance Test; Glucose Transporter Type 4; Hyperglycemia; Liver; Male; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Nicorandil; Nifedipine; Phosphoenolpyruvate Carboxykinase (GTP); Rats; Rats, Wistar; RNA, Messenger; Saralasin; Tetrazoles; Valine; Valsartan

2003
Angiotensin II type 1 receptor blockade improves hyperglycemia-induced endothelial dysfunction and reduces proinflammatory cytokine release from leukocytes.
    Journal of cardiovascular pharmacology, 2007, Volume: 49, Issue:1

    Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cytokines; Endothelium; Humans; Hyperglycemia; Inflammation Mediators; Leukocytes; Male; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan

2007